Using myeloma as a model system, we further demonstrated that blockage of the CRBN cleavage by pharmacological inhibition or genetic depletion of CASP-8 potentiates the anti-myeloma activity of Len in both myeloma cell lines and bone marrow primary myeloma cells. This evidence concerns the gene CRBN and plasma cell myeloma.